Generation and Characterization of Single-Cycle Infectious Canine Influenza A Virus (sciCIV) and Its Use as Vaccine Platform.
Animals
Dogs
Hemagglutinin Glycoproteins, Influenza Virus
Horses
Influenza A Virus, H3N2 Subtype
/ genetics
Influenza A Virus, H3N8 Subtype
/ genetics
Influenza A virus
/ genetics
Influenza Vaccines
Madin Darby Canine Kidney Cells
Mammals
Orthomyxoviridae Infections
/ prevention & control
Vaccines, Attenuated
Canine influenza virus
Green fluorescent protein
Humoral response
Influenza HA-expressing MDCK cells (MDCK-HA)
Influenza vaccine
Reporter gene
Reporter virus
Reverse genetics
Single-cycle infectious influenza A virus
Single-cycle influenza virus
Viral vectors
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
4
2
2022
pubmed:
5
2
2022
medline:
2
4
2022
Statut:
ppublish
Résumé
Influenza A viruses (IAVs) infect a broad range of hosts, including multiple avian and mammalian species. The frequent emergence of novel IAV strains in different hosts, including in humans, results in the need for vigilance and ongoing development of new approaches to fighting or prevent those infections. Canine influenza is a contagious respiratory disease in dogs caused by two subtypes of IAV, the equine-origin H3N8 canine influenza virus (CIV), and the avian-origin H3N2 CIV. A novel approach to influenza vaccination involves single-cycle infectious influenza A viruses (sciIAVs), which are defective for an essential viral gene. They are propagated in complementing cell lines which provide the missing gene in trans. As sciIAV cannot complete their replication cycle in regular cells they are limited to a single round of viral replication. Because of their safety profile and ability to express foreign antigens inside infected cells, sciIAVs have served both as live-attenuated vaccines and as vaccine vectors for the expression of heterologous antigens. Here, we describe experimental procedures for the generation of a single-cycle infectious CIV (sciCIV), where the viral hemagglutinin (HA) gene was exchanged for the gene for green fluorescent protein (GFP). Complementation of the viral HA protein is provided in trans by stable HA-expressing cell lines. Methods for the in vitro characterization of HA deficient but GFP-expressing sciCIV (sciCIV ΔHA/GFP) are described, as well as its use as a potential vaccine.
Identifiants
pubmed: 35118625
doi: 10.1007/978-1-0716-2168-4_13
doi:
Substances chimiques
Hemagglutinin Glycoproteins, Influenza Virus
0
Influenza Vaccines
0
Vaccines, Attenuated
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
227-255Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201400005C
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Shaw M, Palese P (2007) Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA (eds) Fields virology, 5th edn. Lippincott Williams and Wilkins, Philadelphia, PA
Hai R, Schmolke M, Varga ZT et al (2010) PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models. J Virol 84:4442–4450. https://doi.org/10.1128/JVI.02717-09
doi: 10.1128/JVI.02717-09
pubmed: 20181699
pmcid: 2863736
Nogales A, Martinez-Sobrido L, Topham DJ et al (2018) Modulation of innate immune responses by the influenza A NS1 and PA-X proteins. Viruses 10(12):708. https://doi.org/10.3390/v10120708 . [pii] E708v10120708
doi: 10.3390/v10120708
pmcid: 6315843
Gamblin SJ, Skehel JJ (2010) Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 285:28403–28409. https://doi.org/10.1074/jbc.R110.129809
doi: 10.1074/jbc.R110.129809
pubmed: 20538598
pmcid: 2937864
Wille M, Holmes EC (2019) The ecology and evolution of influenza viruses. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a038489 . [pii] cshperspect.a038489
Tong S, Zhu X, Li Y et al (2013) New world bats harbor diverse influenza A viruses. PLoS Pathog 9:e1003657. https://doi.org/10.1371/journal.ppat.1003657
doi: 10.1371/journal.ppat.1003657
pubmed: 24130481
pmcid: 3794996
Nogales A, Martinez-Sobrido L (2016) Reverse genetics approaches for the development of influenza vaccines. Int J Mol Sci 18. https://doi.org/10.3390/ijms18010020 . [pii] E20 ijms18010020
Parrish CR, Murcia PR, Holmes EC (2015) Influenza virus reservoirs and intermediate hosts: dogs, horses, and new possibilities for influenza virus exposure of humans. J Virol 89:2990–2994. https://doi.org/10.1128/JVI.03146-14 . [pii] JVI.03146-14
doi: 10.1128/JVI.03146-14
pubmed: 25540375
Sutton TC (2018) The pandemic threat of emerging H5 and H7 avian influenza viruses. Viruses 10:461. https://doi.org/10.3390/v10090461 . [pii] E461. v10090461
doi: 10.3390/v10090461
pmcid: 6164301
(2015) Outbreak of canine influenza caused by new strain of virus. JAVMA 246:1049
Martinez-Sobrido L, Blanco-Lobo P, Rodriguez L et al (2020) Characterizing emerging canine H3 influenza viruses. PLoS Pathog 16:e1008409. https://doi.org/10.1371/journal.ppat.1008409
doi: 10.1371/journal.ppat.1008409
pubmed: 32287326
pmcid: 7182277
Nogales A, Chauche C, DeDiego ML et al (2017) The K186E amino acid substitution in the canine influenza virus H3N8 NS1 protein restores its ability to inhibit host gene expression. J Virol 91(22):e00877-17. https://doi.org/10.1128/JVI.00877-17
doi: 10.1128/JVI.00877-17
pubmed: 28835506
pmcid: 5660486
Chauche C, Nogales A, Zhu H et al (2018) Mammalian adaptation of an avian influenza A virus involves stepwise changes in NS1. J Virol 92:e01875-17. https://doi.org/10.1128/JVI.01875-17
doi: 10.1128/JVI.01875-17
pubmed: 29237841
pmcid: 5809720
Deshpande MS, Jirjis FF, Tubbs AL et al (2009) Evaluation of the efficacy of a canine influenza virus (H3N8) vaccine in dogs following experimental challenge. Vet Ther 10:103–112
pubmed: 20037964
Rodriguez L, Nogales A, Murcia PR et al (2017) A bivalent live-attenuated influenza vaccine for the control and prevention of H3N8 and H3N2 canine influenza viruses. Vaccine 35:4374–4381. https://doi.org/10.1016/j.vaccine.2017.06.060
doi: 10.1016/j.vaccine.2017.06.060
pubmed: 28709557
Nogales A, Huang K, Chauche C et al (2017) Canine influenza viruses with modified NS1 proteins for the development of live-attenuated vaccines. Virology 500:1–10. https://doi.org/10.1016/j.virol.2016.10.008
doi: 10.1016/j.virol.2016.10.008
pubmed: 27750071
Nogales A, Rodriguez L, Chauche C et al (2017) Temperature-sensitive live-attenuated canine influenza virus H3N8 vaccine. J Virol 91:e02211-16. https://doi.org/10.1128/JVI.02211-16
doi: 10.1128/JVI.02211-16
pubmed: 27928017
pmcid: 5286902
Rodriguez L, Nogales A, Reilly EC et al (2017) A live-attenuated influenza vaccine for H3N2 canine influenza virus. Virology 504:96–106. https://doi.org/10.1016/j.virol.2017.01.020
doi: 10.1016/j.virol.2017.01.020
pubmed: 28167384
Shinya K, Fujii Y, Ito H et al (2004) Characterization of a neuraminidase-deficient influenza a virus as a potential gene delivery vector and a live vaccine. J Virol 78:3083–3088
doi: 10.1128/JVI.78.6.3083-3088.2004
Wacheck V, Egorov A, Groiss F et al (2010) A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis 201:354–362. https://doi.org/10.1086/649428
doi: 10.1086/649428
pubmed: 20039806
Katsura H, Iwatsuki-Horimoto K, Fukuyama S et al (2012) A replication-incompetent virus possessing an uncleavable hemagglutinin as an influenza vaccine. Vaccine 30:6027–6033. https://doi.org/10.1016/j.vaccine.2012.07.059
doi: 10.1016/j.vaccine.2012.07.059
pubmed: 22867723
pmcid: 5626880
Baker SF, Guo H, Albrecht RA et al (2013) Protection against lethal influenza with a viral mimic. J Virol 87:8591–8605. https://doi.org/10.1128/JVI.01081-13
doi: 10.1128/JVI.01081-13
pubmed: 23720727
pmcid: 3719819
Baker SF, Nogales A, Finch C et al (2014) Influenza A and B virus intertypic reassortment through compatible viral packaging signals. J Virol 88:10778–10791. https://doi.org/10.1128/JVI.01440-14
doi: 10.1128/JVI.01440-14
pubmed: 25008914
pmcid: 4178878
Baker SF, Nogales A, Santiago FW et al (2015) Competitive detection of influenza neutralizing antibodies using a novel bivalent fluorescence-based microneutralization assay (BiFMA). Vaccine 33:3562–3570. https://doi.org/10.1016/j.vaccine.2015.05.049 . [pii] S0264-410X(15)00701-X
doi: 10.1016/j.vaccine.2015.05.049
pubmed: 26044496
pmcid: 4480155
Nogales A, Baker SF, Domm W et al (2016) Development and applications of single-cycle infectious influenza A virus (sciIAV). Virus Res 216:26–40. https://doi.org/10.1016/j.virusres.2015.07.013
doi: 10.1016/j.virusres.2015.07.013
pubmed: 26220478
Dudek T, Knipe DM (2006) Replication-defective viruses as vaccines and vaccine vectors. Virology 344:230–239. https://doi.org/10.1016/j.virol.2005.09.020
doi: 10.1016/j.virol.2005.09.020
pubmed: 16364753
Marsh GA, Hatami R, Palese P (2007) Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions. J Virol 81:9727–9736. https://doi.org/10.1128/JVI.01144-07
doi: 10.1128/JVI.01144-07
pubmed: 17634232
pmcid: 2045411
Watanabe S, Watanabe T, Kawaoka Y (2009) Influenza A virus lacking M2 protein as a live attenuated vaccine. J Virol 83:5947–5950. https://doi.org/10.1128/JVI.00450-09
doi: 10.1128/JVI.00450-09
pubmed: 19321619
pmcid: 2681926
Martinez-Sobrido L, Cadagan R, Steel J et al (2010) Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies. J Virol 84:2157–2163. https://doi.org/10.1128/JVI.01433-09
doi: 10.1128/JVI.01433-09
pubmed: 19939917
Victor ST, Watanabe S, Katsura H et al (2012) A replication-incompetent PB2-knockout influenza A virus vaccine vector. J Virol 86:4123–4128. https://doi.org/10.1128/JVI.06232-11
doi: 10.1128/JVI.06232-11
pubmed: 22301144
pmcid: 3318628
Powell TJ, Silk JD, Sharps J et al (2012) Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity. J Virol 86:13397–13406. https://doi.org/10.1128/JVI.01820-12
doi: 10.1128/JVI.01820-12
pubmed: 23015719
pmcid: 3503098
Uraki R, Kiso M, Iwatsuki-Horimoto K et al (2013) A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges. J Virol 87:7874–7881. https://doi.org/10.1128/JVI.00076-13
doi: 10.1128/JVI.00076-13
pubmed: 23658445
pmcid: 3700221
Engelhardt OG (2013) Many ways to make an influenza virus—review of influenza virus reverse genetics methods. Influenza Other Respir Viruses 7:249–256. https://doi.org/10.1111/j.1750-2659.2012.00392.x
doi: 10.1111/j.1750-2659.2012.00392.x
pubmed: 22712782
Nogales A, Perez DR, Santos J et al (2017) Reverse genetics of influenza B viruses. Methods Mol Biol 1602:205–238. https://doi.org/10.1007/978-1-4939-6964-7_14
doi: 10.1007/978-1-4939-6964-7_14
pubmed: 28508223
Neumann G (2020) Influenza reverse genetics—historical perspective. Cold Spring Harbor Perspect Med. https://doi.org/10.1101/cshperspect.a038547
Feng KH, Gonzalez G, Deng L et al (2015) Equine and canine influenza H3N8 viruses show minimal biological differences despite phylogenetic divergence. J Virol 89:6860–6873. https://doi.org/10.1128/JVI.00521-15
doi: 10.1128/JVI.00521-15
pubmed: 25903329
pmcid: 4468500
Quinlivan M, Zamarin D, Garcia-Sastre A et al (2005) Attenuation of equine influenza viruses through truncations of the NS1 protein. J Virol 79:8431–8439. https://doi.org/10.1128/JVI.79.13.8431-8439.2005
doi: 10.1128/JVI.79.13.8431-8439.2005
pubmed: 15956587
pmcid: 1143746
Heix J, Grummt I (1995) Species specificity of transcription by RNA polymerase I. Curr Opin Genet Dev 5:652–656. https://doi.org/10.1016/0959-437x(95)80035-2
doi: 10.1016/0959-437x(95)80035-2
pubmed: 8664554
Ortiz-Riaño E, Cheng BYH, de la Torre JC et al (2013) Arenavirus reverse genetics for vaccine development. J Gen Virol 94:1175–1188. https://doi.org/10.1099/vir.0.051102-0
doi: 10.1099/vir.0.051102-0
pubmed: 23364194
pmcid: 3709625
Nerome K, Kumihashi H, Nerome R et al (1999) Evaluation of immune responses to inactivated influenza vaccines prepared in embryonated chicken eggs and MDCK cells in a mouse model. Dev Biol Stand 98:53–63; discussion 73-74
pubmed: 10494959
Reale MA, Manheimer AJ, Moran TM et al (1986) Characterization of monoclonal antibodies specific for sequential influenza A/PR/8/34 virus variants. J Immunol 137:1352–1358
pubmed: 2426361
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685. https://doi.org/10.1038/227680a0
doi: 10.1038/227680a0
pubmed: 5432063
pmcid: 5432063
Golde WT, Gollobin P, Rodriguez LL (2005) A rapid, simple, and humane method for submandibular bleeding of mice using a lancet. Lab Anim 34:39–43. https://doi.org/10.1038/laban1005-39
doi: 10.1038/laban1005-39
Rodriguez L, Nogales A, Martinez-Sobrido L (2017) Influenza A virus studies in a mouse model of infection. J Vis Exp. https://doi.org/10.3791/55898
Lanza AM, Kim DS, Alper HS (2013) Evaluating the influence of selection markers on obtaining selected pools and stable cell lines in human cells. Biotechnol J 8:811–821. https://doi.org/10.1002/biot.201200364
doi: 10.1002/biot.201200364
pubmed: 23450727
Bussow K (2015) Stable mammalian producer cell lines for structural biology. Curr Opin Struct Biol 32:81–90. https://doi.org/10.1016/j.sbi.2015.03.002
doi: 10.1016/j.sbi.2015.03.002
pubmed: 25804355
Rodrigo WWSI, de la Torre JC, Martínez-Sobrido L (2011) Use of single-cycle infectious lymphocytic choriomeningitis virus to study hemorrhagic fever arenaviruses. J Virol 85:1684–1695. https://doi.org/10.1128/JVI.02229-10
doi: 10.1128/JVI.02229-10
pubmed: 21123370
Lindenmann J, Burke DC, Isaacs A (1957) Studies on the production, mode of action and properties of interferon. Br J Exp Pathol 38:551–562
pubmed: 13479681
pmcid: 2082625
Nogales A, Baker SF, Ortiz-Riano E et al (2014) Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development. J Virol 88:10525–10540. https://doi.org/10.1128/JVI.01565-14
doi: 10.1128/JVI.01565-14
pubmed: 24965472
pmcid: 4178899